|
 Program
Thursday, 6th December, 2007
A. OPENING SESSION
Chaired by:
William Evans, Little Rock, USA
Giovanni Mantovani, Cagliari, Italy
Welcome: John Morley, Stefan Anker, William Evans
1. Cachexia: prevalence and impact in medicine
Ken Fearon, Edinburgh, UK
2. Definition and diagnosis of cachexia / wasting disease
John Morley, St. Louis, USA
3. Similarities and differences of wasting disease
Stefan Anker, Berlin, Germany
4. The cost of cachexia
Wayne Levy, Seattle, USA
|
Friday, 7th December, 2007
B. PLENARY SESSION: Diagnostic criteria of cachexia / wasting disease and their assessment
Chaired by:
John Morley, St. Louis, USA
Stefan Anker, Berlin, Germany
5. Anorexia
Ian Chapman, Adelaide, Australia
6. Decreased muscle strength and fatigue
Florian Strasser, St. Gallen, Switzerland
7. Assessment of body composition
Annemie Schols, Maastricht, The Netherlands
8. Anemia
Gerasimos Filippatos, Athens, Greece
9. Biochemical alterations: inflammation, low albumin
Kamyar Kalantar-Zadeh, Torrance, USA
|
C. CLINICAL TRACK: Cachexia trials
Chaired by:
Aminah Jatoi, Rochester, USA
William Mitch, Houston, USA
10. Ghrelin and ghrelin analogs for wasting disease in CHF and COPD
Piotr Ponikowski, Wroclaw, Poland
11. Update on trials in HIV/AIDS-wasting
Morris Schambelan, San Francisco, USA
12. Growth hormone treatment in severe kidney disease
Viatcheslav Rakov, Zurich, Switzerland
Updates on Clinical Trials – round table discussion
William Evans, John Morley, Stefan Anker
|
D. BASIC TRACK: Ubiquitin-proteasome system
Chaired by:
Alfred Goldberg, Boston, USA
HQ Han, Thousand Oaks, USA
13. Skeletal muscle hypertrophy and atrophy pathways: overview
David Glass, Cambridge, USA
14. Myostatin and ubiquitin
Ravi Kambadur, Singapore
15. Identification of polyubiquitinated substrates of the skeletal muscle proteasome
Didier Attaix, Clermond-Ferrand, France
16. Thinking outside the box: the example of rho- and rac-kinase inhibitors
Stephan von Haehling, London, UK
17. Short plenary poster presentation n(abstract 1.04)
Milan Holecek, Hradec Kralove, Czech Republic
|
12.00 - 14.00 Lunch
12.15 - 13.45 Poster sessions
PO 1. Cachexia mechanisms
PO 2. Cachexia in cancer
PO 3. Methodology studies
E. CLINICAL TRACK: Cancer cachexia
Chaired by:
Kamyar Kalantar-Zadeh, Torrance, USA
Marc Hellerstein, Berkeley, USA
18. The clinical problem: epidemiology & pathophysiology
Aminah Jatoi, Rochester, USA
19. The effects of cancer on skeletal musculature
Vickie Baracos, Edmonton, Canada
20. Causes of death and cardiac problems
Mathias Rauchhaus, Berlin, Germany
21. Treatment on cancer cachexia: clinical trials update
Glenn Lesser, Winston-Salem, USA
22. Short plenary poster presentation (abstract 4.62-64)
Jochen Springer, Berlin, Germany
|
F. BASIC TRACK: Muscle metabolism
Chaired by:
Herbert Lochs, Berlin, Germany
Annemie Schols, Maastricht, The Netherlands
23. Is it possible to separate the metabolic effects of cachexia from inactivity
William Evans, Little Rock, USA
24. Myostatin
HQ Han, Thousand Oaks, USA
25. Biomarkers for muscle wasting from tissue
William Mitch, Houston, USA
26. Biomarkers for muscle wasting from blood
Stephan von Haehling, Berlin, Germany
|
G. PLENARY SESSION: Pathophysiology of tissue wasting
Chaired by:
Luigi Ferrucci, Baltimore, USA
Fillippo Rossi-Fanelli, Rome, Italy
27. “Prometheus” basic science in cachexia lecture: past, present and future trends in cancer cachexia research
Giovanni Mantovani, Cagliari, Italy
28. Muscle events contributing to and limiting muscle wasting
Alfred Goldberg, Boston, USA
29. Stem cells and muscle
Nadia Rosenthal, Rome, Italy
30. Of bears, frogs, meat, mice and men: insights into muscle loss and fat deposition
Miranda Grounds, Perth, Australia
17.45 – 19.15 General poster discussion |
Saturday, 8th December, 2007
H. PLENARY SESSION: Wasting disease in chronic illness – common pathways
Chaired by:
David Thomas, St. Louis, USA
Connie Bales, Durham, USA
31. Chronic kidney disease
Joel Kopple, Los Angeles, USA
32. Role of intestinal function in wasting disease
Herbert Lochs, Berlin, Germany
33. Chronic heart failure
Piotr Ponikowski, Wroclaw, Poland
34. Chronic obstructive pulmonary disease
Matthias John, Prerow, Germany
|
I. BASIC TRACK: New treatment approaches
Chaired by:
Robert Wolfe, Little Rock, USA
Daniel Marks, Portland, USA
35. ACE inhibitors
Marco Pahor, Gainesville, USA
36. Nitric Oxide: friend or foe in cachexia
Thomas Thum, Würzburg, Germany
37. Ghrelin and ghrelin analogs
Rakesh Datta, Boston, USA
38. Immune modulation
Anthony Cerami, Ossining, USA
|
K . CLINICAL TRACK: Sarcopenia
Chaired by:
John Morley, St. Louis, USA
Jochen Springer, Berlin, Germany
39. Epidemiology
Richard Baumgartner, Louisville, USA
40. General pathophysiology
Luigi Ferrucci, Baltimore, USA
41. Cell dath regulation and ageing
Volker Adams, Leipzig, Germany
42. Clinical insights
Cornel Sieber, Nuremberg, Germany
43. Short plenary poster presentation (poster 5.73)
Maurits Vandewoude, Antwerpen, Belgium
|
12:00-14:00 Lunch
12:15 – 13:45 Poster sessions
PO 4. Intervention studies
PO 5. Human cachexia - various
PO 6. Cachexia mechanisms
L . CLINICAL TRACK: Nutraceuticals and Orexigenics
Chaired by:
William Evans, Little Rock, USA
William Mitch, Houston, USA
44. Feeding and wasting disease: the role of nutraceuticals
Connie Bales, Durham, USA
45. Eicosopentanoic acid, BCAA and carnitine
Fillippo Rossi-Fanelli, Rome, Italy
46. Orexigenics
David Thomas, St. Louis, USA
47. Regulation of feeding
Daniel Marks, Portland, USA
|
M . BASIC TRACK: Growth factors
Chaired by:
HQ Han, Thousand Oaks, USA
Joel Kopple, Los Angeles, USA
48. SARMs
Shalender Bhasin, Los Angeles, USA
49. Mechanogrowth factor/ IGF-I
Geoff Goldspink, London, UK
50. Ghrelin
Akio Inui, Kagoshima, Japan
51. Pathophysiology of AIDS Cachexia
Marc Hellerstein, Berkeley, USA
|
N. PLENARY SESSION: Muscle
Chaired by:
Nadia Rosenthal, Rome, Italy
Michael Schuster, New York, USA
52. “Hippocrates” clinical research in cachexia lecture: the metabolic basis of muscle loss
Robert Wolfe, Little Rock, USA
53. Muscle wasting in cancer and ageing: cachexia versus sarcopenia
Josep Argiles, Barcelona, Spain
54. Mitochondria and muscle
Christiaan Leeuwenburgh, Gainesville, USA
55. Muscle and fat tissue interaction
Liat Mintz, East Brunswick, USA
|
From 20.00 Anti-cachexia dinner (beach party)
Sunday, 9th December, 2007
O. PLENARY SESSION: Debates
Chaired by:
Stefan Anker, Berlin, Germany
John Morley, St. Louis, USA
DEBATE 1: Are cytokines always involved in the pathogenesis of cachexia?
56. Pro
Maurizio Muscaritoli, Rome, Italy
57. Con
Michael Schuster, New York, USA
DEBATE 2: What needs to be preserved in acute cachexia – fat or muscle tissue ?
58. Fat
Wolfram Doehner, Berlin, Germany
59. Muscle
William Evans, Little Rock, USA
DEBATE 3: Is nutritional support essential for anabolics to work in cachexia?
60. Pro
Arny Ferrando, Little Rock, USA
61. Con
Khursheed N. Jeejeebhoy, Ontario, Canada
|
P. PLENARY SESSION: Meeting highlights and close
Chaired by:
John Morley, St. Louis, USA
Josep Argiles, Barcelona, Spain
62. Meeting highlights: basic science
Josep Argiles, Barcelona, Spain
63. Meeting highlights: pathophysiology
William Evans, Little Rock, USA
64. Meeting highlights: treatment studies
Stefan Anker, Berlin, Germany
|
Awards ceremony: Young Investigator Awards & Poster Prizes
|
|
|
Program
